Literature DB >> 27712593

Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway.

Yu Wang1, Hui Leng, Hui Chen, Lei Wang, Nan Jiang, Xin Huo, Bin Yu.   

Abstract

Ubiquitin-conjugating enzyme E2T (UBE2T), a member of the E2 family, was found to be overexpressed in a great many cancers such as bladder cancer, lung cancer, and prostate cancer. However, there have been no reports on the role of UBE2T in osteosarcoma. In this study, we tried to make the effects of UBE2T on osteosarcoma clear. The study results showed that UBE2T was overexpressed in osteosarcoma tissues and cell lines. Moreover, UBE2T knockdown inhibited osteosarcoma cell proliferation, migration, and invasion. We also observed that UBE2T downregulation could suppress the activity of the PI3K/Akt signaling pathway. Therefore, we concluded that UBE2T exerted its inhibitory effects on osteosarcoma cells via suppressing the PI3K/Akt signaling pathway. These findings indicated that UBE2T may be a potential therapeutic target for osteosarcoma treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27712593     DOI: 10.3727/096504016X14685034103310

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  29 in total

1.  Genipin inhibits the growth of human bladder cancer cells via inactivation of PI3K/Akt signaling.

Authors:  Zheng Li; Tian-Biao Zhang; Dong-Hui Jia; Wen-Qi Sun; Chao-Liang Wang; Ao-Zheng Gu; Xiao-Ming Yang
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

2.  Heat shock transcription factor 1 promotes the proliferation, migration and invasion of osteosarcoma cells.

Authors:  Zhenhua Zhou; Yan Li; Qi Jia; Zhiwei Wang; Xudong Wang; Jingjing Hu; Jianru Xiao
Journal:  Cell Prolif       Date:  2017-04-01       Impact factor: 6.831

3.  UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer.

Authors:  Wei Huang; Hongyan Huang; Yuzhen Xiao; Lei Wang; Tingting Zhang; Xiaoling Fang; Xiaomeng Xia
Journal:  Cell Cycle       Date:  2022-02-07       Impact factor: 5.173

4.  Screening of potential biomarkers and their predictive value in early stage non-small cell lung cancer: a bioinformatics analysis.

Authors:  Hongbin Tu; Meihong Wu; Weiling Huang; Lixin Wang
Journal:  Transl Lung Cancer Res       Date:  2019-12

5.  Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Authors:  Javier Perez-Peña; Verónica Corrales-Sánchez; Eitan Amir; Atanasio Pandiella; Alberto Ocana
Journal:  Sci Rep       Date:  2017-12-13       Impact factor: 4.379

6.  Casticin inhibits breast cancer cell migration and invasion by down-regulation of PI3K/Akt signaling pathway.

Authors:  Li Fan; Yi Zhang; Qiuhong Zhou; Ying Liu; Baolan Gong; Jieyu Lü; Hui Zhu; Guijuan Zhu; Yingping Xu; Guangrong Huang
Journal:  Biosci Rep       Date:  2018-11-30       Impact factor: 3.840

7.  UBE2T promotes proliferation via G2/M checkpoint in hepatocellular carcinoma.

Authors:  Li-Li Liu; Ji-Min Zhu; Xiang-Nan Yu; Hai-Rong Zhu; Xuan Shi; Enkhnaran Bilegsaikhan; Hong-Ying Guo; Jian Wu; Xi-Zhong Shen
Journal:  Cancer Manag Res       Date:  2019-09-13       Impact factor: 3.989

8.  UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.

Authors:  Peng Hao; Bo Kang; Yapeng Li; Wenqi Hao; Feihong Ma
Journal:  Mol Med Rep       Date:  2019-06-03       Impact factor: 2.952

9.  The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma.

Authors:  Hua Yu; Han Wang; Wei Dong; Zhen-Ying Cao; Rong Li; Chao Yang; Wen-Ming Cong; Hui Dong; Guang-Zhi Jin
Journal:  PeerJ       Date:  2020-01-27       Impact factor: 2.984

10.  UBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma.

Authors:  Xiaoyuan Wang; Yang Liu; Xue Leng; Kui Cao; Wentao Sun; Jinhong Zhu; Jianqun Ma
Journal:  Pathol Oncol Res       Date:  2021-04-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.